CN110944979A - Odm-201晶型及其制备方法和药物组合物 - Google Patents

Odm-201晶型及其制备方法和药物组合物 Download PDF

Info

Publication number
CN110944979A
CN110944979A CN201780092656.2A CN201780092656A CN110944979A CN 110944979 A CN110944979 A CN 110944979A CN 201780092656 A CN201780092656 A CN 201780092656A CN 110944979 A CN110944979 A CN 110944979A
Authority
CN
China
Prior art keywords
odm
crystalline form
solvent
crystal form
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201780092656.2A
Other languages
English (en)
Other versions
CN110944979B (zh
Inventor
盛晓红
盛晓霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOLIPHARMA LLC
Original Assignee
SOLIPHARMA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOLIPHARMA LLC filed Critical SOLIPHARMA LLC
Priority to CN202310202127.0A priority Critical patent/CN116396220A/zh
Publication of CN110944979A publication Critical patent/CN110944979A/zh
Application granted granted Critical
Publication of CN110944979B publication Critical patent/CN110944979B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及N‑((S)‑1‑(3‑(3‑氯‑4‑氰基苯基)‑1H‑吡唑‑1‑基)丙‑2‑基)‑5‑(1‑羟基乙基)‑1H‑吡唑‑3‑甲酰胺(即ODM‑201)的晶型，与已知的ODM‑201相比，本发明的ODM‑201晶型具有一种或多种改进的特性。本发明还涉及所述ODM‑201晶型的制备方法，其药物组合物及其在制备用于治疗核受体、特别是类固醇受体、尤其是雄激素受体(`AR)依赖型疾病和症状的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN201780092656.2A 2017-08-09 2017-08-09 Odm-201晶型及其制备方法和药物组合物 Active CN110944979B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310202127.0A CN116396220A (zh) 2017-08-09 2017-08-09 Odm-201晶型及其制备方法和药物组合物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/096547 WO2019028689A1 (zh) 2017-08-09 2017-08-09 Odm-201晶型及其制备方法和药物组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310202127.0A Division CN116396220A (zh) 2017-08-09 2017-08-09 Odm-201晶型及其制备方法和药物组合物

Publications (2)

Publication Number Publication Date
CN110944979A true CN110944979A (zh) 2020-03-31
CN110944979B CN110944979B (zh) 2023-05-12

Family

ID=65273230

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780092656.2A Active CN110944979B (zh) 2017-08-09 2017-08-09 Odm-201晶型及其制备方法和药物组合物
CN202310202127.0A Pending CN116396220A (zh) 2017-08-09 2017-08-09 Odm-201晶型及其制备方法和药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310202127.0A Pending CN116396220A (zh) 2017-08-09 2017-08-09 Odm-201晶型及其制备方法和药物组合物

Country Status (3)

Country Link
US (1) US11236073B2 (zh)
CN (2) CN110944979B (zh)
WO (1) WO2019028689A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116396220A (zh) * 2017-08-09 2023-07-07 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3495352T (pt) 2016-08-26 2021-05-03 Crystal Pharmaceutical Suzhou Co Ltd Formas de cristal de um antagonista de recetor de androgénio, método de preparação e utilização das mesmas
WO2022036782A1 (zh) * 2020-08-18 2022-02-24 拜耳消费者护理股份有限公司 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016120530A1 (en) * 2015-01-30 2016-08-04 Orion Corporation A carboxamide derivative and its diastereomers in stable crystalline form
CN109641851A (zh) * 2016-08-26 2019-04-16 苏州科睿思制药有限公司 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
BR112013026905B1 (pt) 2011-04-21 2021-09-14 Orion Corporation Compostos de carboxamida moduladora do receptor de andrógeno e seu uso no tratamento e prevenção de câncer de próstata, bem como composições farmacêuticas compreendendo os ditos compostos
CN110944979B (zh) * 2017-08-09 2023-05-12 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016120530A1 (en) * 2015-01-30 2016-08-04 Orion Corporation A carboxamide derivative and its diastereomers in stable crystalline form
CN109641851A (zh) * 2016-08-26 2019-04-16 苏州科睿思制药有限公司 一种雄激素受体拮抗剂药物的晶型及其制备方法和用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116396220A (zh) * 2017-08-09 2023-07-07 杭州领业医药科技有限公司 Odm-201晶型及其制备方法和药物组合物

Also Published As

Publication number Publication date
US11236073B2 (en) 2022-02-01
US20200216422A1 (en) 2020-07-09
CN110944979B (zh) 2023-05-12
CN116396220A (zh) 2023-07-07
WO2019028689A1 (zh) 2019-02-14

Similar Documents

Publication Publication Date Title
RU2414470C2 (ru) Кристаллические формы соединения тиазолидиндиона и способ его получения
AU2016253550B2 (en) A crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2- carboxamide hydrochloride monohydrate
JP2014530805A (ja) アジルサルタンの結晶形並びにその製造及び使用
CN114409633A (zh) 一种受体激动剂的晶型及其制备方法和药物组合物
CN110944979B (zh) Odm-201晶型及其制备方法和药物组合物
CN110612292A (zh) 奥扎莫德加成盐晶型、制备方法及药物组合物和用途
EP3322704B1 (en) Crystalline form of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazepin-4(5h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections
CN110582497B (zh) Galunisertib的晶型及其制备方法和药物组合物
CN111194312A (zh) 依地普仑的新盐和固态形式
CN111801323A (zh) 玻玛西尼甲磺酸盐晶型及其制备方法和药物组合物
TWI662031B (zh) １－｛２－氟－４－［５－（４－異丁基苯基）－１，２，４－噁二唑－３－基］－苄基｝－３－吖丁啶羧酸的晶型
TWI680983B (zh) 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體
CN110582279B (zh) 2-(6-甲基-吡啶-2-基)-3-基-[6-酰胺基-喹啉-4-基]-5,6-二氢-4H-吡咯并[1,2-b]吡唑的共晶，其制备方法和药物组合物
WO2015096119A1 (zh) 氯卡色林盐及其晶体、其制备方法和用途
CN113149998B (zh) 2-吲哚啉螺环酮类化合物或其盐、溶剂合物的无定形形式或结晶形式
CN117561248A (zh) 伊沃替尼和其盐的晶型及其制备方法和用途
JP2023513176A (ja) Ｅｐ４受容体アンタゴニストの多形体、その調製方法および用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant